We are live on
!
Find out more
PAI
Palo Alto Investors Portfolio holdings
AUM
$654M
1-Year Est. Return
77.8%
This Fund
S&P 500
This Quarter
Est. Return
+3.08%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.24B
AUM Growth
+$30.7M
(+2.5%)
Cap. Flow
+$41.5M
Cap. Flow
% of AUM
3.35%
Top 10 Holdings %
Top 10 Hldgs %
87.1%
Holding
32
New
2
Increased
4
Reduced
3
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NovoCure
NVCR
|
+$33.9M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$12.1M |
| 3 |
NVRO
NEVRO CORP.
NVRO
|
+$5.38M |
| 4 |
STAAR Surgical
STAA
|
+$1.67M |
| 5 |
Relmada Therapeutics
RLMD
|
+$526K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PRVB
Provention Bio, Inc. Common Stock
PRVB
|
+$9.42M |
| 2 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
+$1.3M |
| 3 |
Vanda Pharmaceuticals
VNDA
|
+$1.02M |
| 4 |
Prothena Corp
PRTA
|
+$408K |
| 5 |
PKBO
Peak Bio, Inc. Common Stock
PKBO
|
+$314K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.22% |
| 2 | Financials | 1.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
BioMarin Pharmaceuticals
BMRN
$13.3B
| $159M | 12.82% |
1,831,035
| – | – |
|
2
United Therapeutics
UTHR
$22.7B
| $139M | 11.19% |
627,514
| – | – |
|
|
RVNC
3
DELISTED
Revance Therapeutics, Inc.
RVNC
| $132M | 10.69% |
5,228,609
-41,600
| -0.8% | -$1.3M |
|
|
FOLD
4
DELISTED
Amicus Therapeutics
FOLD
| $132M | 10.68% |
10,524,022
| – | – |
|
5
Insmed
INSM
$29.4B
| $124M | 10.04% |
5,889,491
| – | – |
|
|
6
Prothena Corp
PRTA
$468M
| $113M | 9.14% |
1,657,458
-6,319
| -0.4% | -$408K |
|
7
Biogen
BIIB
$30.6B
| $109M | 8.77% |
381,282
| – | – |
|
|
8
STAAR Surgical
STAA
$1.25B
| $72.3M | 5.84% |
1,374,822
+27,500
| +2% | +$1.67M |
|
9
Acadia Pharmaceuticals
ACAD
$5.06B
| $57.6M | 4.65% |
2,405,793
| – | – |
|
|
SAGE
10
DELISTED
Sage Therapeutics
SAGE
| $40.4M | 3.27% |
859,517
| – | – |
|
11
Align Technology
ALGN
$12.5B
| $26.4M | 2.13% |
74,605
| – | – |
|
|
12
NovoCure
NVCR
$2.02B
| $24M | 1.94% |
578,118
+545,328
| +1,663% | +$33.9M |
|
13
eHealth
EHTH
$40.4M
| $22M | 1.78% |
2,739,379
+50,000
| +2% | +$400K |
|
14
Alkermes
ALKS
$8.29B
| $18.9M | 1.53% |
603,400
| – | – |
|
15
Syndax Pharmaceuticals
SNDX
$1.82B
| $12.8M | 1.04% |
612,600
| – | – |
|
|
16
Sarepta Therapeutics
SRPT
$1.81B
| $10.8M | 0.87% |
+94,030
| New | +$12.1M |
|
17
Karyopharm Therapeutics
KPTI
$44.4M
| $10.2M | 0.82% |
378,392
| – | – |
|
18
AnaptysBio
ANAB
$1.64B
| $8.77M | 0.71% |
431,224
| – | – |
|
|
NVRO
19
DELISTED
NEVRO CORP.
NVRO
| $4.73M | 0.38% |
+186,259
| New | +$5.38M |
|
20
Gossamer Bio
GOSS
$86.1M
| $4.16M | 0.34% |
3,465,152
| – | – |
|
21
Cytokinetics
CYTK
$10.8B
| $3.64M | 0.29% |
111,717
| – | – |
|
22
Travere Therapeutics
TVTX
$5.74B
| $2.55M | 0.21% |
166,069
| – | – |
|
|
23
Vanda Pharmaceuticals
VNDA
$304M
| $2.14M | 0.17% |
324,073
-158,624
| -33% | -$1.02M |
|
|
24
Relmada Therapeutics
RLMD
$484M
| $1.8M | 0.15% |
732,400
+190,300
| +35% | +$526K |
|
25
Mirum Pharmaceuticals
MIRM
$6.02B
| $1.67M | 0.14% |
64,700
| – | – |
|
Similar funds
RRA
AG
BL
CG
SCM
GAMA
PIM
ACA
Palo Alto Investors's Q2 2023 Portfolio in Review
As of Q2 2023, Palo Alto Investors held 32 positions worth $1.24B, up 2.5% from $1.21B the previous quarter. Its ten largest holdings account for 87% of the portfolio.
Palo Alto Investors deployed $41.5M of net new capital in Q2 2023, opening 2 new positions and adding to 4 existing holdings. Its largest new stake was Sarepta Therapeutics: 94,030 shares worth $10.8M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Revance Therapeutics, Inc., an estimated $1.3M trimmed.
- Palo Alto Investors's largest Q2 2023 buy was Sarepta Therapeutics: 94,030 shares worth $10.8M.
- Palo Alto Investors added most to NovoCure in Q2 2023, an estimated $33.9M increase.
- Palo Alto Investors's biggest Q2 2023 reduction was Revance Therapeutics, Inc., cutting an estimated $1.3M.
- Palo Alto Investors fully exited Provention Bio, Inc. Common Stock in Q2 2023, selling an estimated $9.42M.
- Palo Alto Investors's ten largest holdings make up 87% of its $1.24B portfolio in Q2 2023.
- Palo Alto Investors opened 2 new positions and closed 2 in Q2 2023.
- Palo Alto Investors's portfolio value rose 2.5% quarter-over-quarter to $1.24B.
Based on Palo Alto Investors's 13F filing for Q2 2023, filed 14 Aug 2023.